Iatrogenic cushing's syndrome post intralesional triamcinolone acetonide in oral submucous fibrosis: 2 case reports.
Betel nut chewing
Iatrogenic cushing syndrome
Oral potentially malignant disorders
Oral submucous fibrosis
Triamcinolone acetonide injection
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
28 10 2023
28 10 2023
Historique:
received:
19
06
2023
accepted:
08
10
2023
medline:
30
10
2023
pubmed:
29
10
2023
entrez:
29
10
2023
Statut:
epublish
Résumé
Oral Submucous Fibrosis (OFMF) is an oral potentially malignant disorder (OPMDs), strongly linked to betel quid chewing. It exhibits a significantly higher rate of malignant transformation compared to other OPMDs. The use of Intralesional Triamcinolone Acetonide Injection has emerged as a highly effective treatment option and has become the cornerstone of managing this condition. A 44-year-old female and a 40-year-old male presented with burning sensation and limited mouth opening, leading to diagnosis of OSMF. Both patients were treated with Triamcinolone Acetonide (TAC) Intralesional injections. Following a few months of treatment, a significant improvement in mouth opening was observed. However, both patients began experiencing symptoms such as facial rounding (mooning of the face), a buffalo hump, uneven hair growth, and swelling in the lower extremities. Upon recognizing these symptoms as indicative of Cushing's Syndrome, the administration of TAC injection was discontinued. Both patients were referred to a higher-level medical facility for confirmatory tests, which revealed elevated cortisol levels in both morning (Cortisol A.M) and evening (Cortisol P.M). TAC injection has been established as an effective treatment for OSMF. However, it is crucial to closely monitor patients for any adverse effects resulting from the treatment, which may arise from high dosage or increased frequency.
Sections du résumé
BACKGROUND
Oral Submucous Fibrosis (OFMF) is an oral potentially malignant disorder (OPMDs), strongly linked to betel quid chewing. It exhibits a significantly higher rate of malignant transformation compared to other OPMDs. The use of Intralesional Triamcinolone Acetonide Injection has emerged as a highly effective treatment option and has become the cornerstone of managing this condition.
CASE PRESENTATION
A 44-year-old female and a 40-year-old male presented with burning sensation and limited mouth opening, leading to diagnosis of OSMF. Both patients were treated with Triamcinolone Acetonide (TAC) Intralesional injections. Following a few months of treatment, a significant improvement in mouth opening was observed. However, both patients began experiencing symptoms such as facial rounding (mooning of the face), a buffalo hump, uneven hair growth, and swelling in the lower extremities. Upon recognizing these symptoms as indicative of Cushing's Syndrome, the administration of TAC injection was discontinued. Both patients were referred to a higher-level medical facility for confirmatory tests, which revealed elevated cortisol levels in both morning (Cortisol A.M) and evening (Cortisol P.M).
CONCLUSION
TAC injection has been established as an effective treatment for OSMF. However, it is crucial to closely monitor patients for any adverse effects resulting from the treatment, which may arise from high dosage or increased frequency.
Identifiants
pubmed: 37898806
doi: 10.1186/s12903-023-03505-x
pii: 10.1186/s12903-023-03505-x
pmc: PMC10612248
doi:
Substances chimiques
Triamcinolone Acetonide
F446C597KA
Hydrocortisone
WI4X0X7BPJ
Glucocorticoids
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
813Informations de copyright
© 2023. The Author(s).
Références
Burns. 2013 Jun;39(4):549-57
pubmed: 23092701
J Pers Med. 2022 Aug 01;12(8):
pubmed: 36013221
Subst Use Misuse. 2020;55(9):1443-1449
pubmed: 32569547
Front Pharmacol. 2022 Apr 20;13:825266
pubmed: 35517828
Int J Mol Sci. 2020 Sep 30;21(19):
pubmed: 33008091
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):690-697
pubmed: 33072506
Nutr J. 2013 May 20;12:67
pubmed: 23688186
J Oral Pathol Med. 2020 Sep;49(8):803-808
pubmed: 32652683
Oral Oncol. 2012 Mar;48(3):200-2
pubmed: 22070918
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Aug;122(2):200-9
pubmed: 27422418
Natl J Maxillofac Surg. 2020 Jul-Dec;11(2):307-308
pubmed: 33897201